

**KURZPROTOKOLL**  
**Checkmate CA209-817**

<b>Öffentlicher Titel</b>	Nivolumab und Ipilimumab bei fortgeschrittenem Nicht-kleinzelligem Lungenkrebs
<b>Wissenschaftl. Titel</b>	A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants With Advanced Malignancies.
<b>Kurztitel</b>	Checkmate CA209-817
<b>Studienart</b>	multizentrisch, prospektiv, Therapiestudie, randomisiert, offen/unverblindet, Pharma-Studie, zweiarmig
<b>Studienphase</b>	Phase III/IV
<b>Erkrankung</b>	Lunge: Lungenkrebs: Nicht kleinzelliges Lungenkarzinom (NSCLC) - Zweitlinie oder höher Lunge: Lungenkrebs: Nicht kleinzelliges Lungenkarzinom (NSCLC) - Erstlinie
<b>Einschlusskriterien</b>	<ul style="list-style-type: none"><li>- Histologically confirmed Stage 4 or recurrent non-small cell lung cancer</li><li>- Eastern Cooperative Oncology Group (ECOG) score 0-1 (Physically able to carry out light housework or office work through to being fully active as you were before cancer)</li><li>- No prior systemic anticancer therapy (including EGFR and ALK inhibitors)</li><li>- Tissue or Programmed death-ligand 1 (PD-L1) results available</li></ul>
<b>Ausschlusskriterien</b>	<ul style="list-style-type: none"><li>- Untreated brain metastases</li><li>- An active malignancy that requires concurrent intervention</li><li>- Active, known or suspected autoimmune disease</li><li>- Carcinomatous meningitis, which means there is inflammation of the covering of the brain, caused by cancer</li></ul>
<b>Alter</b>	18 Jahre und älter
<b>Sponsor</b>	Bristol-Myers Squibb
<b>Registrierung in anderen Studienregistern</b>	ClinicalTrials.gov NCT02869789 EudraCT 2016-002621-10